Tugba Sismanlar Eyuboglu
Overview
Explore the profile of Tugba Sismanlar Eyuboglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akgul Erdal M, Nayir Buyuksahin H, Sen V, Ayzit Kilinc A, Cokugras H, Dogan G, et al.
Turk J Pediatr
. 2025 Mar;
67(1):22-30.
PMID: 40084730
Background: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants are essential for determining eligibility for CFTR modulator drugs (CFTRms). In contrast to Europe and the USA, the treatment eligibility profile of...
2.
Marczak H, Krenke K, Griese M, Peradzynska J, Lange J, Kulus M, et al.
Chest
. 2025 Mar;
PMID: 40054602
Background: Persistent tachypnea of infancy (PTI)/neuroendocrine cell hyperplasia of infancy (NEHI) is a form of childhood interstitial lung disease (chILD) that predominantly affects young children. Although it is one of...
3.
Metin Cakar N, Selcuk Balci M, Kilic Baskan A, Arslan H, Unal F, Koc Y, et al.
Respiration
. 2025 Jan;
:1-11.
PMID: 39809249
Background: Advances in neonatal and pediatric intensive care have improved patient survival rates, emphasizing the need for respiratory support in cases of chronic respiratory failure, resulting in the establishment of...
4.
Upper Extremity Exercise Capacity and Muscle Oxygenation in Patients With Primary Ciliary Dyskinesia
Mutlu S, Bosnak Guclu M, Sismanlar Eyuboglu T, Tana Aslan A
Pediatr Pulmonol
. 2025 Jan;
60(1):e27470.
PMID: 39785198
Background And Objectives: Patients with primary ciliary dyskinesia (PCD) have a reduction in exercise capacity from the early stages. Although there are studies investigating these patients' lower extremity exercise capacity...
5.
Emiralioglu N, Cakir B, Sertcelik A, Yalcin E, Kiper N, Sen V, et al.
Pediatr Pulmonol
. 2024 Jul;
59(11):2956-2966.
PMID: 38980199
Background: The decline in pulmonary function is a predictor of disease progression in patients with cystic fibrosis (CF). This study aimed to determine the decline rate of percent predicted forced...
6.
Nayir Buyuksahin H, Emiralioglu N, Yalcin E, Sen V, Selimoglu Sen H, Arslan H, et al.
Pediatr Pulmonol
. 2024 May;
59(10):2499-2506.
PMID: 38771207
Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all...
7.
Yilmaz A, Pekcan S, Sismanlar Eyuboglu T, Hangul M, Arslan H, Ayzit Kilinc A, et al.
Eur J Pediatr
. 2024 Jan;
183(4):1831-1838.
PMID: 38265526
Since the outbreak of the Syrian civil war in 2011, the population of Arab refugees in Turkey has rapidly increased. While cystic fibrosis (CF) is believed to be rare among...
8.
Nayir-Buyuksahin H, Emiralioglu N, Ayzit Kilinc A, Girit S, Yalcin E, Sismanlar Eyuboglu T, et al.
Eur J Pediatr
. 2023 Oct;
183(1):295-304.
PMID: 37875631
The childhood interstitial lung diseases (chILD) Turkey registry (chILD-TR) was established in November 2021 to increase awareness of disease, and in collaboration with the centers to improve the diagnostic and...
9.
Sismanlar Eyuboglu T, Tana Aslan A, Asfuroglu P, Kunt N, Ersoy A, Kose M, et al.
Pediatr Pulmonol
. 2023 Aug;
58(11):3106-3112.
PMID: 37530491
Background: Airway inflammation starts in early life in cystic fibrosis (CF) and limited, objective markers are available to help identify infants with increased inflammation. We aimed to investigate neutrophil, lymphocyte...
10.
Uytun S, Cinel G, Eryilmaz Polat S, Ozkan Tabakci S, Kiper N, Yalcin E, et al.
Pediatr Pulmonol
. 2023 Jun;
58(9):2505-2512.
PMID: 37278544
Background: Cystic fibrosis (CF) is an autosomal recessive disorder caused by CF transmembrane conductance regulator (CFTR) genetic variants. CFTR modulators improve pulmonary function and reduce respiratory infections in CF. This...